Supreme Court Protects ‘Skinny Label’ Generic Drug Pathway (2)

The Supreme Court said a district court judge was right to dismiss Amarin Pharma Inc.'s infringement suit over claims its ...
pharmaphorum

SCOTUS backs generic firm Hikma in skinny label dispute

In a unanimous, nine-to-zero ruling, the SCOTUS judges have ruled that Hikma's generic of Amarin Pharma's Vascepa (icosapent ...
The American Journal of Managed Care

Medication Adherence and Use of Generic Drug Therapies

Generic prescribing was associated with improved medication adherence in 2 of 5 study conditions, but $0 copayments were associated with improved adherence across all conditions. We analyzed 2001-2004 ...
JD Supra

U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals

In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed ...
The American Journal of Managed Care

Trends in Medicare Part D Coverage of Generics With Equivalent Brand-Name Drugs

High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug ...